BA3311

N/A

Report date: 2026/03/19 17:16:33

Base Information

Drug NameBA3311

Drug Alias NameBA3311

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-CD3

TargetsEpidermal growth factor receptor erbB1T cell surface glycoprotein CD3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesBioAtla Inc

China Registration ClassN/A

Develop Information

Active CompaniesBioAtla Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A